Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

What excipients are combined with ruxolitinib in apotex's medication?
Combivent generic equivalent?
Pramlintide acetate price?
Dabrafenib and trametinib price?
When will a generic version of xiaflex be available?

Tagrisso maker?

See the DrugPatentWatch profile for Tagrisso

Tagrisso is manufactured by AstraZeneca [1].

What is Tagrisso used for?

Tagrisso (osimertinib) is a targeted therapy used to treat certain types of non-small cell lung cancer (NSCLC) [2]. Specifically, it is indicated for patients with epidermal growth factor receptor (EGFR) exon 19 deletions or EGFR exon 21 (L858R) substitutions as a first-line treatment, and for patients with EGFR T790M mutations who have progressed on or after prior EGFR tyrosine kinase inhibitor (TKI) therapy [2].

When is Tagrisso's patent expected to expire?

Patent expiry dates for pharmaceuticals can be complex, involving multiple patents covering different aspects of the drug, such as the compound itself, its manufacturing process, and its use in specific indications [3]. Information on the specific patent expiry timelines for Tagrisso can be found on resources like DrugPatentWatch.com [3]. Generally, patent protection for a drug can extend for many years, with exclusivity periods often lasting around 20 years from the filing date, though this can be influenced by various factors including extensions and litigation [3].

Can generic versions of Tagrisso be made available?

The availability of generic versions of Tagrisso, also known as biosimilars in the case of biologic drugs, is contingent upon patent expiry and regulatory approval [4]. Once the relevant patents expire and regulatory hurdles are cleared, other manufacturers may be able to produce and market generic or biosimilar versions of the drug, potentially leading to lower prices [4].

What are the main competitors to Tagrisso?

Tagrisso competes with other EGFR inhibitors used in the treatment of NSCLC [5]. These include earlier generation TKIs like gefitinib and erlotinib, as well as other third-generation TKIs [5]. The competitive landscape is dynamic, with ongoing research and development of new treatments for NSCLC.

What are the potential side effects of Tagrisso?

Common side effects reported for Tagrisso include diarrhea, rash, dry skin, and stomatitis [2]. More serious potential side effects can include interstitial lung disease or pneumonitis, heart problems, and blood clot formation [2]. Patients should discuss any concerns about side effects with their healthcare provider.



Other Questions About Tagrisso :

Where is tagrisso made? Patent tagrisso? Tagrisso potencia? Tagrisso patent expiration canada? Tagrisso patent expiry date? Tagrisso fda approval date? Tagrisso news?

AI-Drug Label Prescribing Information Alignment Report

35
35%
Grade D

Poor

Not Aligned

Patient Risk: Moderate

Summary

Indications match the provided label excerpts, but multiple safety-related claims are unsupported by the provided sections (notably several adverse events described as “common” and an unsupported claim about “blood clot formation”).

Category Scores

Indication
98
Excellent
Warnings
70
Good
AdverseReactions
10
Poor

Accurate Statements

Tagrisso is indicated for patients with EGFR exon 19 deletions as a first-line treatment.
Supported by 1.3 First-line Treatment of EGFR Mutation-Positive Metastatic NSCLC.
Tagrisso is indicated for patients with EGFR exon 21 (L858R) substitutions as a first-line treatment.
Supported by 1.3 First-line Treatment of EGFR Mutation-Positive Metastatic NSCLC.
Tagrisso is indicated for patients with EGFR T790M mutations who have progressed on or after prior EGFR tyrosine kinase inhibitor (TKI) therapy.
Supported by 1.5 Previously Treated EGFR T790M Mutation-Positive Metastatic NSCLC.
More serious potential side effects of Tagrisso include interstitial lung disease or pneumonitis.
Supported by 5.1 Interstitial Lung Disease/Pneumonitis.

Unsupported Statements

Tagrisso is manufactured by AstraZeneca.
No manufacturing/company statement is provided in the available label sections.
Common side effects of Tagrisso include diarrhea.
No adverse reaction list (including diarrhea) is present in the provided label excerpts.
Common side effects of Tagrisso include rash.
No adverse reaction list (including rash) is present in the provided label excerpts.
Common side effects of Tagrisso include dry skin.
No adverse reaction list (including dry skin) is present in the provided label excerpts.
Common side effects of Tagrisso include stomatitis.
No adverse reaction list (including stomatitis) is present in the provided label excerpts.
More serious potential side effects of Tagrisso include blood clot formation.
No provided label section mentions blood clot formation (thromboembolic events) in the supplied excerpts.

Contradictions

Important Omissions

The AI response does not include label-supported monitoring/dosing modification details related to ILD/pneumonitis or cardiomyopathy (e.g., withholding/discontinuation and cardiac monitoring/LVEF assessment) that are material to safely describing serious warnings.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Moderate
Multiple adverse-event claims are presented as “common” without support in the provided label excerpts, and at least one serious adverse event (“blood clot formation”) is unsupported; this could mislead regarding safety expectations. Some serious warnings (ILD/pneumonitis) are supported.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Moderate

Recommendation

Not Aligned

Primary Issue
Unsubstantiated adverse reaction claims (several “common” events and “blood clot formation”) not supported by the provided prescribing-information excerpts; company/manufacturer statement also unsupported.

Suggested Improvement
Remove or revise unsupported adverse-event statements to only those explicitly supported by the label excerpts provided; avoid adding “common”/incidence descriptors unless present in the label. Limit safety statements to label-supported warnings such as ILD/pneumonitis and cardiomyopathy, and use the label’s terminology.

Drug Brand Mention Assessment

Branding Score
55
Visibility
56
Mentioned
Ranking
#1
Sentiment
55
Recommendation Status
mentioned only
Brand Perception
Best Known For

“Tagrisso (osimertinib) is a targeted therapy used to treat certain types of non-small cell lung cancer (NSCLC)”

Core Claims
  • “Tagrisso is manufactured by AstraZeneca.”
  • “Tagrisso (osimertinib) is a targeted therapy used to treat certain types of non-small cell lung cancer (NSCLC).”
  • It is indicated for “EGFR exon 19 deletions” or “EGFR exon 21 (L858R) substitutions as a first-line treatment.”
  • It is indicated for “EGFR T790M mutations who have progressed on or after prior EGFR tyrosine kinase inhibitor (TKI) therapy.”
  • Side effects can include “diarrhea, rash, dry skin, and stomatitis” and more serious effects like “interstitial lung disease or pneumonitis.”
Differentiators
  • Targeted therapy “(osimertinib)” for NSCLC
  • Indications tied to specific EGFR mutation types (exon 19 deletions, exon 21 L858R, T790M)
  • First-line use for exon 19 deletions/L858R substitutions
  • Used after prior EGFR TKI therapy for T790M mutations
Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
AstraZeneca 6%
50 # No